Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
12:41am, Wednesday, 15'th Apr 2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announ
Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway
03:18pm, Tuesday, 14'th Apr 2026
Revolution Medicines (RVMD) remains a 'Strong Buy' following statistically significant phase 3 RASolute 302 results for daraxonrasib in 2nd-line metastatic PDAC. Company's daraxonrasib achieved median
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
01:35pm, Tuesday, 14'th Apr 2026
Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for global regulatory filings.
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
04:01pm, Monday, 13'th Apr 2026
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announ
Revolution Medicines (RVMD) Hits All-Time Highs After Groundbreaking Cancer Trial Results
12:14pm, Monday, 13'th Apr 2026
Revolution Medicines (RVMD) has reached all-time highs following the announcement of remarkable results from the pivotal Phase 3 RASolute 302 trial. The trial d
How This Biotech Stock Skirted Today's Selloff
10:34am, Monday, 13'th Apr 2026
Revolution Medicines Inc (NASDAQ:RVMD) stock is brushing off the broad market selloff this morning, last seen up 35.5% to trade at $131.35, and earlier hitting a record high of $135.81.
Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough
10:13am, Monday, 13'th Apr 2026
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential br
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
10:10am, Monday, 13'th Apr 2026
The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
09:45am, Monday, 13'th Apr 2026
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemothera
This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.
09:11am, Monday, 13'th Apr 2026
Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.
Stock Market Live April 13: S&P 500 (SPY) Back in the Red as Oil Gushes Higher
08:31am, Monday, 13'th Apr 2026
Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocks Wall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identi
Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
08:06am, Monday, 13'th Apr 2026
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-s
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
08:00am, Monday, 13'th Apr 2026
Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60%
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
01:49pm, Friday, 10'th Apr 2026
Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen.
